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DEVELOPMENT OF SANOFI PASTEUR TETRAVALENT DENGUE VACCINE
Jean LANG(1) 
With almost 50% of the world population at risk and an estimated 
annual burden that includes 230M infections, 2M severe cases and 
25000 deaths, dengue is a major public health concern. Brazil is a 
priority country for dengue vaccination as it accounts for 70% of all 
reported cases in Americas (1998-2009) and > 1 million clinical cases 
reported in 2010. After decades of research by different groups around 
the world, dengue vaccine development reached a major milestone in 
2010 with the initiation of the first phase III clinical trial to investigate 
a candidate vaccine. This vaccine is the Sanofi Pasteur CYD tetravalent 
dengue vaccine (TDV) which is now being evaluated for protective 
efficacy in large scale trials in Latin America and south-east Asia as part 
of an extensive clinical development program in both regions. The CYD 
TDV candidate comprises four recombinant, live, attenuated vaccines 
(CYD-1–4) based on a yellow fever vaccine 17D (YF17D) backbone, 
each expressing the pre-membrane and envelope genes of one of the four 
dengue virus serotypes. The vaccine is genetically and phenotypically 
stable, non-hepatotropic, less neurovirulent than YF17D, and does not 
infect mosquitoes by the oral route. In vitro and in vivo preclinical 
studies showed that CYD TDV induces controlled stimulation of human 
dendritic cells, and significant immune responses in monkeys that cross-
react against a panel of approximately 20 different circulating strains per 
serotype. Scale up and industrialization are being conducted in parallel 
with preclinical and clinical development to fulfill the needs of phase II/
III trials, and to anticipate and facilitate supply and access to vaccine in 
the countries where the dengue disease burden makes it an urgent public 
health priority. As of September 2011, the vaccine has been administered 
to more than 11,000 children and adults in completed or ongoing studies 
and no safety concerns have arisen. Given with a three-dose regimen, 
vaccination induces balanced immune responses against all four serotypes 
in the large majority of vaccinees. Preexisting flavivirus immunity favors 
quicker and higher immune responses to CYD TDV, without adversely 
effecting clinical safety or increasing vaccine viremia. The observed level 
and nature of the cellular immune responses in humans are consistent with 
the good safety and immunogenicity profile of the vaccine. Preliminary 
results of an ongoing efficacy and large scale safety study in Thai children 
are expected by the end of 2012 and we envisage the availability of this 
vaccine for high disease burden countries in the next three to five years.
The worldwide expansion of dengue fever is major public health 
concern. Dengue has become the most common tropical disease in 
Latin America and Asia Pacific, and worldwide dengue is second only 
to malaria. Almost 50% of the world population lives in areas at risk 
for dengue. Each year more than 230 million people are infected; two 
million patients develop severe disease, especially children (90%), and 
25,000 patients die1-3.
Dengue is spreading in different areas and the burden of disease has 
increased substantially in recent decades. Brazil accounts for the majority 
of cases registered in the Americas, with more than one million dengue 
cases, almost 100,000 hospitalizations and more than 600 deaths in 20104.
There is no specific treatment against dengue and vector control 
measures have limited impact, particularly with the development of 
insecticide resistance among the mosquito population. The availability 
of a dengue vaccine would represent a major advance in the control of 
the disease2,4-6.
In the last 40 years, different approaches have been used by academic 
and industrial laboratories to develop dengue vaccine candidates. 
These include live attenuated virus (LAV), recombinant virus vectors 
expressing dengue envelope (E) antigens, purified inactivated virus 
(PIV), recombinant subunit vaccine, virus-like particles (VPLs), and 
DNA vaccines6-8.
Live vaccines have been shown to produce robust, long-lasting and 
broad humoral and cellular immune response, but are associated with 
a higher rate of adverse events, and cannot be used in some at-risk 
groups, such as in immunocompromised people. Inactivated vaccines 
have reduced potential for reactogenicity, but tend to have a diminished 
ability to induce broad and durable immune responses6.
Several dengue vaccines are at various stages of evaluation. The 
early enthusiasm about the tetravalent LAV dengue vaccines, developed 
with classic empirical techniques of attenuation by serial cell passages, 
was impacted by the difficulty of achieving an appropriate balance 
between immunogenicity and reactogenicity. The vaccine strains 
were genetically and phenotypically unstable, and caused dengue-
like syndromes (fever, leucopenia, and rash) in high proportion of 
participants in early clinical trials6. A second generation of dengue 
vaccines was developed to surmount these problems. In the early 2000´s, 
Acambis discovery scientists (now Sanofi Pasteur) designed a second 
generation of flavivirus vaccines, using an innovative recombinant 
DNA technology to produce four live, attenuated vaccine viruses 
based on yellow fever 17D vaccine strain, one per dengue serotype. 
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Each recombinant virus (CYD1, CYD2, CYD3 and CYD4) was 
constructed by removing the genes encoding the premembrane (prM) 
and envelope (E) proteins from the yellow fever 17D virus and inserting 
the corresponding genes from a dengue virus8. Using this technology, 
Sanofi Pasteur has preclinically, clinically and industrially developed 
a tetravalent dengue vaccine, combining the four CYD vaccine viruses 
into a single vaccine. This dengue candidate vaccine is the first to reach 
the milestone of clinical phase III studies8.
There are many hurdles to the development of a successful dengue 
vaccine, including:
- The lack of an animal model that reproduces human disease. Non-
human primates can be infected but do not develop disease.
- Four dengue virus serotypes can cause serious diseases, and the 
immunity conferred by an infection is serotype-specific, with only a 
short period of cross-protection against infection by other serotypes.
- There is a theoretical risk of immunopotentiation or sensitization 
after sequential monovalent infections, which has been proposed 
to be caused, in part, by antibody dependent enhancement (ADE), 
associated with heterologous non-neutralizing antibodies and/or the 
waning of homologous neutralizing antibody titers.
- Neutralizing antibodies against the dengue envelop proteins are 
considered to be essential for protection, but there is no known 
correlate of protection, and candidate vaccines must be studied 
for efficacy in large numbers of individuals, in accordance with 
guidelines for the clinical evaluation, production and quality control 
recommended by WHO.
The ideal dengue vaccine would have a good safety profile, the 
ability to elicit broad and durable immune responses against all four 
serotypes, and be suitable for use in children and adults. Live vaccines 
usually confers long lasting protection, but the development of multivalent 
live vaccines is complicated by the potential for interference between 
serotypes which can result in the immunodominance of one or two 
serotypes, and can necessitate several doses to achieve an antibody 
response to all serotypes6,7. 
 
Dengue affects people in all age groups. Virus circulation differs 
between regions, even within the same country. Vaccination schedules, 
including for other flaviviral diseases (yellow fever and Japanese 
encephalitis), differ between countries. How to fit a new vaccine into 
existing national immunization programs therefore requires careful 
consideration. It is therefore necessary to study the potential of 
interference of a dengue vaccine candidate when co-administered with 
established vaccines7,8.
Pragmatic issues, such as storage and the logistics of distributing a 
high number of doses while maintaining the cold-chain, and strategies to 
reach compliance with the recommended schedule and achieve suitable 
vaccine coverage rates require discussion with health authorities before 
implementation of a dengue vaccine9.
The effective use of the vaccine in the field will require partnerships 
and collaboration among public and private sectors of endemic countries 
to define where and how to introduce the vaccine. The ultimate goal will 
be to design effective vaccination programs to alleviate the growing 
global disease burden and pharmacoeconomic disruptive impact of 
dengue viruses2.
Other challenges relate to the industrialization of vaccine production 
for the four vaccine viruses, and the manufacturing process scale-up 
necessary to supply large-scale Phase III trials to demonstrate the 
protective efficacy, and to prepare for the subsequent launch in case of 
licensure7-10. Sanofi Pasteur has constructed new facilities to scale up 
the production, and facilitate supply and access to vaccine as soon as 
possible8.
Extensive pre-clinical research has demonstrated the genotypic and 
phenotypic stability of the CYD vaccine strains and has shown that 
reversion to virulence or the recombination with other flaviviruses is 
highly unlikely. The risk of inadvertent environmental dissemination of 
the CYD viruses via mosquitoes has also been shown to be minimal7,8,11-13. 
Other issue related to a candidate vaccine is its capability to protect 
against different genotypes of dengue, and we had shown that our 
candidate vaccine induces cross-reactive responses against a panel of 
about 20 different circulating strains per serotype8. “Cross-neutralizing 
antibody responses against circulating DENV field isolates after human 
vaccination with a tetravalent dengue vaccine14,15. 
Phase I and II clinical trials with a 3-dose vaccination regimen over 
12 months demonstrate that this candidate vaccine elicits neutralizing 
antibodies against all four serotypes in both children and adults with a 
good safety profile13,16,17. 
The global clinical development program includes 45,000 participants 
from 15 countries8. To date (February 2012), more than 23,000 
individuals, aged two to 45 years have received at least one dose of CYD 
dengue vaccine in completed or ongoing studies8. Vaccine safety is being 
monitored by an Independent Data Monitoring Committee (IDMC), an 
independent group of international experts, and so far no safety signals 
have been identified. A pooled analysis of safety data available in June 
2011, including 1,728 subjects from 5 Phase I studies (USA, Mexico, 
Philippines) and eight phase II studies (six completed) also revealed no 
safety concerns. Reports of solicited reactions and unsolicited adverse 
events were similar to those of the control vaccines, and tend to decrease 
in frequency after second and third vaccinations compared to first 
vaccination. Vaccine viremia is undetectable in the large majority of 
vaccinees, and when detected the level of viremia has remained low. There 
have been no reports of dengue-like syndrome or serious adverse events 
related to this vaccine, in contrast to live attenuated vaccines developed 
by conventional attenuation techniques. Furthermore, the safety profile 
has been shown to be comparable in individuals with or without prior 
exposure to dengue of other flavivirus, via infection or vaccination (YF, 
JE)7,8,14. While all available data show that the vaccine’s safety profile is 
good, with no safety signals detected after the vaccination of more than 
23,000 vaccinees so far, the potential risk of very rare adverse events 
cannot be determined until the licensure and introduction of the vaccine. 
Other questions that cannot be definitively answered until after vaccine 
introduction concern herd protection, efficacy of alternative schedules 
(intention to treat), and the duration of protection in endemic and non-
endemic areas.
The first phase III study was initiated in 2010 in Australia to evaluate 
lot-to-lot consistency. The first efficacy study, including 4,000 children 
(4-11 years) is ongoing in a highly endemic area of Thailand, and the 
results are expected for the end of 2012. Positive results from this 
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study, conducted in an area where the force of infection is high would 
represent the first time clinical efficacy has been demonstrated with a 
dengue vaccine, and would allow us to consider initial submission to the 
regulatory authorities in some countries8. 
To expand the efficacy database in different countries, two other phase 
III efficacy studies are ongoing in Asia (Thailand, Indonesia, Malaysia, 
Viet Nan, Philippines), with planned inclusion of about 10,000 children 
(2-14 years) and Latin America (Colombia, Mexico, Honduras, Porto 
Rico and Brazil) where the number of enrolled children aged 9-16 years 
is expected to be 20,000. 
In conclusion, the CYD tetravalent dengue vaccine candidate 
has demonstrated its capacity to induce broad and balanced immune 
responses against the four dengue serotypes in children and adults from 
endemic and non-endemic areas with a 3 dose vaccination regimen at 
0, 6, 12 months. All available data show the vaccine’s safety profile to 
be good, with no safety signals detected after the vaccination of more 
than 23,000 vaccinees so far. The outcome of the first dengue vaccine 
efficacy trial will be known by the end of 2012 and if positive will pave 
the way for initial licensure and the immunization of populations against 
this burdensome disease.
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